Altogether, in our study, which aimed to select a TKI that could be used as a resistant cancer cell-sensitizing monotherapy from among 13 TKIs, we identified low-dose crizotinib to strongly sensitize P-gp-overexpressing antimitotic drug-resistant cancer cells via the induction of late apoptosis and G2 arrest. This evidence concerns the gene PGP and cancer.